Octreotide
- Generic Name
- Octreotide
- Brand Names
- Bynfezia, Mycapssa, Sandostatin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 83150-76-9
- Unique Ingredient Identifier
- RWM8CCW8GP
- Background
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threat...
- Indication
Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide an...
- Associated Conditions
- Acromegaly, Diarrhea, Metastatic Carcinoid Tumors
- Associated Therapies
- Long-term maintenance therapy
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
- Conditions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03812939
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 160
- Registration Number
- NCT03624517
- Locations
- 🇺🇸
The Ohio state University, Columbus, Ohio, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸University of Florida Health, Jacksonville, Florida, United States
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 76
- Registration Number
- NCT03571594
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 15
- Registration Number
- NCT03520569
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
- Conditions
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT03289741
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering West Harrison, Harrison, New York, United States
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT03179995
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Ginkgo Leaf Center for Rare Disorders
- Target Recruit Count
- 1965
- Registration Number
- NCT03158090
- Locations
- 🇨🇳
China Acromegaly Organization, Guangzhou, Guangdong, China
RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Theodor Bilharz Research Institute
- Target Recruit Count
- 105
- Registration Number
- NCT03061604
- Locations
- 🇧🇪
Erasme Hospital , ULB, Brussels, Belgium
🇪🇬Theodor Bilharz Research Institute, Giza, Egypt
Prevention of Postoperative Pancreatic Fistula by Somatostatin
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 655
- Registration Number
- NCT03000946
- Locations
- 🇫🇷
Cochin Hospital, Paris, France
🇫🇷La Pitié Salpêtrière Hospital, Paris, France
Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Saint Vincent's Hospital, Korea
- Target Recruit Count
- 282
- Registration Number
- NCT02920567
- Locations
- 🇰🇷
the Catholic University of Korea St. Vincent's Hospital, Suwon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.